BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C, Rando-Muñoz FJ. Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol 2015; 21(42): 12083-12090 [PMID: 26576093 DOI: 10.3748/wjg.v21.i42.12083] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
2 Dooghaie Moghadam A, Eslami P, Dowlati Beirami A, Iravani S, Farokhi E, Mansour-Ghanaei A, Hashemi MR, Aghajanpoor Pasha M, Mehrvar A, Nassiri-Toosi M. An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation. Middle East J Dig Dis 2021;13:5-14. [PMID: 34712432 DOI: 10.34172/mejdd.2021.197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Muhammad H, Zaffar D, Tehreem A, Ting P, Simsek C, Gokcan H, Gurakar A, Idilman R. HBV/HDV management after liver transplantation: Review. Journal of Liver Transplantation 2021;4:100046. [DOI: 10.1016/j.liver.2021.100046] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shen Z, Wang Z, Jiang Y, Wu T, Zheng S. Early outcomes of implanting larger-sized grafts in deceased donor liver transplantation. ANZ J Surg 2020;90:1352-7. [PMID: 32691510 DOI: 10.1111/ans.16132] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Dobrindt EM, Keshi E, Salim Y, Gillespie A, Saipbaev A, Schöning W, Öllinger R, Pratschke J, Eurich D. Hepatitis B Immunoglobulin discontinuation in long-term liver transplant patients. Transpl Infect Dis 2020;22:e13303. [PMID: 32367631 DOI: 10.1111/tid.13303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis 2019;23:493-509. [PMID: 31266623 DOI: 10.1016/j.cld.2019.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Ajayi T, Luu H, Saberi B, Hamilton JP, Konduk BT, Özşeker B, Al Khalloufi K, Pustavoitau A, Philosophe B, Cameron AM, Gürakar A. Role of nucleoside/nucleotide analogues and low-dose hepatitis B immune globülin in prophylaxis of hepatitis B recurrence among cadaveric liver transplant recipients. Turk J Gastroenterol 2018;29:61-6. [PMID: 29391309 DOI: 10.5152/tjg.2018.17595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Patel SS, Leung DH. Hepatitis B immunity in the pediatric liver transplant population. Curr Opin Pediatr 2016;28:653-8. [PMID: 27367054 DOI: 10.1097/MOP.0000000000000391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
10 Flisiak R, Halota W, Jaroszewicz J, Juszczyk J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Wawrzynowicz-Syczewska M; Polish Group of Experts for HBV. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017;3:35-46. [PMID: 28856289 DOI: 10.5114/ceh.2017.67626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]